Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of the Safety and Tolerability of DTI-015 in Patients With Recurrent Glioblastoma Multiforme

NCT00006656 is registered in ClinicalTrials.gov with Direct Therapeutics as lead sponsor.

NCT NCT00006656
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00006656 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of the Safety and Tolerability of DTI-015 in Patients With Recurrent Glioblastoma Multiforme
Lead sponsor
Direct Therapeutics
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2000
Completion date
Not reported
Enrollment
Not reported
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors